The OASIS 1 phase 3 RCT demonstrated the superiority of oral semaglutide 50 mg vs
With that caveat, here is what the published Phase 3 data say at peak dose, in adults with obesity and without diabetes: The roughly 6-percentage-point gap between retatrutide and tirzepatide at peak dose, sustained across more than 2,000 participants, is the data point payers and prescribers will spend the next year arguing about
The magnitude of GLP-1 enhancement achievable through diet differs substantially from pharmaceutical interventions, and patients should understand these distinctions clearly
Very short or dysfunctional telomeres can contribute to cellular senescence or genomic instability
Endpoints and assessments The primary endpoint was change in HbA 1c from baseline to week 26, and the confirmatory secondary endpoint was change in body weight (kg) from baseline to week 26
The gut microbiome and depression: a review